SCHEMBL20932686

SCHEMBL20932686

Clc1ccc(CN2CN=C(SCc3ccc(Br)cc3CSC3=NCN(Cc4ccc(Cl)c(Cl)c4)CN3)NC2)cc1Cl

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP1A2 P05177 2/20 0.45
▸ CYP2D6 P10635 2/20 0.45
▸ HIF1A Q16665 1/20 0.45
▸ KMT2A Q03164 4/20 0.42
▸ MEN1 O00255 1/20 0.42
▸ TSHR P16473 2/20 0.37
▸ SMN1; SMN2 Q16637 2/20 0.37
▸ POLB P06746 1/20 0.37
▸ SIGMAR1 Q99720 1/20 0.36
▸ MAPK1 P28482 2/20 0.36
▸ HSD17B10 Q99714 1/20 0.36
▸ MAPT P10636 2/20 0.35
▸ GFER P55789 1/20 0.35
▸ GPR183 P32249 1/20 0.35
▸ PTPRC P08575 1/20 0.35
▸ PTPRG P23470 1/20 0.35
▸ USP2 O75604 1/20 0.34
▸ DAO P14920 1/20 0.34
▸ MDH2 P40926 1/20 0.33
▸ BACE1 P56817 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30130216 1.00 CYP1A2 (0.45) CYP1A2CYP2D6HIF1AKMT2AMEN1
SCHEMBL20920814 0.91 SOS1 (0.39) CYP1A2CYP2D6HIF1AKMT2AMEN1
SCHEMBL20920181 0.91 CYP1A2 (0.44) CYP1A2CYP2D6HIF1AKMT2AMEN1
SCHEMBL20920834 0.90 CYP1A2 (0.51) CYP1A2CYP2D6HIF1AKMT2AMEN1
SCHEMBL22263088 0.82 CYP1A2 (0.42) CYP1A2CYP2D6HIF1AKMT2AMEN1
SCHEMBL22275605 0.80 CYP1A2 (0.38) CYP1A2CYP2D6HIF1AKMT2AMEN1
SCHEMBL22275736 0.80 CYP1A2 (0.50) CYP1A2CYP2D6HIF1AKMT2AMEN1
SCHEMBL20932660 0.79 KMT2A (0.45) CYP1A2CYP2D6KMT2AMEN1TSHR
SCHEMBL30130108 0.79 KMT2A (0.45) CYP1A2CYP2D6KMT2AMEN1TSHR
SCHEMBL20920185 0.79 CYP1A2 (0.42) CYP1A2CYP2D6HIF1AKMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250092020-A1 IDO/TDO Inhibitor GENERAL INCORPORATED ASSOCIATION PHARMA VALLEY PROJECT SUPPORTING ORGANIZATION (JP) 2025-03-20 — — US disclosed
US-12209079-B2 IDO/TDO inhibitor GENERAL INCORPORATED ASSOCIATION PHARMA VALLEY PROJECT SUPPORTING ORGANIZATION (JP) 2025-01-28 — — US disclosed
US-20200239452-A1 IDO/TDO Inhibitor CANBAS CO., LTD. (JP) 2020-07-30 — — US disclosed
US-20200239452-A1 IDO/TDO Inhibitor CANBAS CO., LTD. (JP) 2020-07-30 — — US disclosed
WO-2019078246-A1 IDO/TDO INHIBITOR 一般社団法人ファルマバレープロジェクト支援機構 2019-04-25 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12209079-B2 IDO/TDO inhibitor IDO1, IDO2, TDO2 CYP1A2 363/4885CYP2D6 575/4885HIF1A 3666/4885
US-20200239452-A1 IDO/TDO Inhibitor IDO1, IDO2, TDO2 CYP1A2 363/4885CYP2D6 575/4885HIF1A 3666/4885
US-20250092020-A1 IDO/TDO Inhibitor IDO1, IDO2, TDO2 CYP1A2 363/4885CYP2D6 575/4885HIF1A 3666/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback